Skip to main content
Saturday 20 December 2025
BlueSky linkedin youtube
header links
  • Get Newsletters
  • Media Kit
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO 2025
    • BIO 2025
    • C-Suite Innovators
    • ESMO 2025
    • Frontiers Health 2025
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

News

News
NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

UroGen’s urothelial cancer drug bags FDA approval

The FDA has approved UroGen’s Jelmyto (mitomycin gel) as the first therapy to treat low-grade upper tract urothelial cancer (UTUC). 

News
OpdivoLarge

BMS eyes August FDA verdict for Opdivo/Yervoy in first-line ...

News
Alnylam

Alnylam files its third RNAi drug lumasiran in rare kidney d...

News
FDA says all ranitidine drugs should be recalled on safety concerns

FDA says all ranitidine drugs should be recalled on safety c...

News
Vascepa

Amarin hit hard as generics loom for fish oil drug Vascepa

News
Zolgensma

Novartis closes on EU approval for SMA gene therapy Zolgensm...

  • Load more results

Editor's Picks

  1. AC Immune says Parkinson's drug slows progression
  2. UK confirms lower clawback rate for NHS medicines
  3. Antibiotic is first approval in FDA national priority scheme
  4. Agreement reached on EU's new pharma legislation
  5. UK teams up with Singapore on healthtech regulation
Patients
pharmaphorum podcast Episode 234, Amy Bucher, Lirio

Delivering the right behavioural ingredients for the moment,...

Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Sales & Marketing
Physicians walking and using tablet devices
Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company